EDITORIAL   |  December 12, 2019   FDA Approves Frontline Atezolizumab Plus Chemo for Metastatic Non-Squamous NSCLC The FDA approved atezolizumab (Tecentriq) in combination with chemotherapy for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. Read more ADVERTISEMENT   FDA Approves Abbreviated New Drug Applications for Everolimus Generic Drug Teva Pharmaceuticals and Par Pharmaceuticals submitted 2 abbreviated new drug applications for the everolimus generic. Read more   ICYMI: Patients with Endometrial Cancer Pose High Risk of Dying from Cardiovascular Disease A study published in the European Heart Journal suggested that patients with endometrial cancer pose a very high risk of dying from cardiovascular diseases in the first year after diagnosis, supporting early involvement of cardiologists for patients with endometrial cancer. Read more